338 related articles for article (PubMed ID: 22788128)
1. Subcutaneous allergen immunotherapy for allergic disease: examining efficacy, safety and cost-effectiveness of current and novel formulations.
Cox L; Calderón M; Pfaar O
Immunotherapy; 2012 Jun; 4(6):601-16. PubMed ID: 22788128
[TBL] [Abstract][Full Text] [Related]
2. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
Calderon MA; Casale TB; Nelson HS; Demoly P
J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison.
Di Bona D; Plaia A; Leto-Barone MS; La Piana S; Di Lorenzo G
J Allergy Clin Immunol; 2012 Nov; 130(5):1097-1107.e2. PubMed ID: 23021885
[TBL] [Abstract][Full Text] [Related]
4. [Role of allergen-specific immunotherapy (desensitization) for the treatment of allergies in Germany. Current situation].
Kleine-Tebbe J; Ackermann-Simon J; Hanf G
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2012 Mar; 55(3):343-50. PubMed ID: 22373847
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of sublingual vs subcutaneous allergen immunotherapy.
Pokladnikova J; Krcmova I; Vlcek J
Ann Allergy Asthma Immunol; 2008 May; 100(5):482-9. PubMed ID: 18517082
[TBL] [Abstract][Full Text] [Related]
6. Does evidence support the use of cat allergen immunotherapy?
Dhami S; Agarwal A
Curr Opin Allergy Clin Immunol; 2018 Aug; 18(4):350-355. PubMed ID: 29870462
[TBL] [Abstract][Full Text] [Related]
7. Novel routes for allergen immunotherapy: safety, efficacy and mode of action.
Moingeon P; Mascarell L
Immunotherapy; 2012 Feb; 4(2):201-12. PubMed ID: 22339462
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of subcutaneous immunotherapy for allergic rhinoconjunctivitis and asthma: a systematic review.
Erekosima N; Suarez-Cuervo C; Ramanathan M; Kim JM; Chelladurai Y; Segal JB; Lin SY
Laryngoscope; 2014 Mar; 124(3):616-27. PubMed ID: 23832632
[TBL] [Abstract][Full Text] [Related]
9. A comparison of immunotherapy delivery methods for allergen immunotherapy.
Klimek L; Pfaar O
Expert Rev Clin Immunol; 2013 May; 9(5):465-74; quiz 475. PubMed ID: 23634740
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of specific subcutaneous immunotherapy in patients with allergic rhinitis and allergic asthma.
Brüggenjürgen B; Reinhold T; Brehler R; Laake E; Wiese G; Machate U; Willich SN
Ann Allergy Asthma Immunol; 2008 Sep; 101(3):316-24. PubMed ID: 18814456
[TBL] [Abstract][Full Text] [Related]
11. Allergen immunotherapy: where is it now?
Nelson HS
J Allergy Clin Immunol; 2007 Apr; 119(4):769-79. PubMed ID: 17337297
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of grass pollen subcutaneous immunotherapy (SCIT) compared to sublingual immunotherapy (SLIT) and symptomatic treatment in Austria, Spain, and Switzerland.
Brüggenjürgen B; Reinhold T
J Med Econ; 2018 Apr; 21(4):374-381. PubMed ID: 29271271
[TBL] [Abstract][Full Text] [Related]
13. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study.
Yukselen A; Kendirli SG; Yilmaz M; Altintas DU; Karakoc GB
Int Arch Allergy Immunol; 2012; 157(3):288-98. PubMed ID: 22041501
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous injection immunotherapy for optimal effectiveness.
Nelson HS
Immunol Allergy Clin North Am; 2011 May; 31(2):211-26, viii. PubMed ID: 21530815
[TBL] [Abstract][Full Text] [Related]
15. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy.
Kiel MA; Röder E; Gerth van Wijk R; Al MJ; Hop WC; Rutten-van Mölken MP
J Allergy Clin Immunol; 2013 Aug; 132(2):353-60.e2. PubMed ID: 23651609
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous versus sublingual immunotherapy for allergic rhinitis and/or asthma.
Bahceciler NN; Cobanoglu N
Immunotherapy; 2011 Jun; 3(6):747-56. PubMed ID: 21668312
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous immunotherapy.
Roche AM; Wise SK
Int Forum Allergy Rhinol; 2014 Sep; 4 Suppl 2():S51-4. PubMed ID: 25182356
[TBL] [Abstract][Full Text] [Related]
18. Dose dependence of efficacy but not of safety in sublingual immunotherapy.
Frati F; Incorvaia C; Marcucci F; Sensi L; Di Cara G; Puccinelli P; Dal Bo S
Monaldi Arch Chest Dis; 2006 Mar; 65(1):38-40. PubMed ID: 16700192
[TBL] [Abstract][Full Text] [Related]
19. Is faster safer? Cluster versus short conventional subcutaneous allergen immunotherapy.
Quiralte J; Justicia JL; Cardona V; Dávila I; Moreno E; Ruiz B; García MA
Immunotherapy; 2013 Dec; 5(12):1295-303. PubMed ID: 24283840
[TBL] [Abstract][Full Text] [Related]
20. Sublingual immunotherapy for treating respiratory allergy: a review on its effectiveness and suitability.
Incorvaia C; Fuiano N; Leo G
Clin Ter; 2010; 161(6):543-7. PubMed ID: 21181085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
